Polo-like Kinase 1 Inhibitors and Their Potential Role in Anticancer Therapy, with a Focus on NSCLC

被引：58
作者：
Medema, Rene H. [1 ,2 ]
Lin, Chia-Chi [3 ]
Yang, James Chih-Hsin [3 ,4 ,5 ]
机构：
[1] Univ Med Ctr Utrecht, Dept Med Oncol, Utrecht, Netherlands
[2] Univ Med Ctr Utrecht, Canc Genom Ctr, Utrecht, Netherlands
[3] Natl Taiwan Univ, Dept Oncol, Taipei 10764, Taiwan
[4] Natl Taiwan Univ, Grad Inst Oncol, Taipei 10764, Taiwan
[5] Natl Taiwan Univ, Canc Res Ctr, Taipei 10764, Taiwan
来源：
CLINICAL CANCER RESEARCH | 2011年 / 17卷 / 20期
关键词：
CELL LUNG-CANCER; PHASE-III TRIAL; SMALL INTERFERING RNA; CHEMOTHERAPY REGIMENS; TUMOR-GROWTH; BI; 2536; PLK1; MUTATIONS; DOCETAXEL; CARBOPLATIN;
D O I：
10.1158/1078-0432.CCR-11-0541
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Cytotoxic platinum-doublet chemotherapy that includes antimitotic agents is a current standard of care in advanced non-small cell lung cancer (NSCLC). Microtubule-targeting antimitotics, taxanes, and Vinca alkaloids are effective anticancer therapeutics that affect both dividing and nondividing cells. A new generation of antimitotic agents that target regulatory proteins-mitotic kinases and kinesins-has the potential to overcome the limitations related to the role of tubulin in nondividing cells that are associated with traditional antimitotics. This review concentrates on Polo-like kinase 1, a key regulator of mitosis, outlines a rationale for its development as an anticancer target, and discusses data from preclinical and clinical studies of Plk1 inhibitors with a particular focus on NSCLC. Clin Cancer Res; 17(20); 6459-66. (C) 2011 AACR.
引用
收藏
页码：6459 / 6466
页数：8
相关论文
共 63 条
  • [1] The novel mouse Polo-like kinase 5 responds to DNA damage and localizes in the nucleolus
    Andrysik, Zdenek
    Bernstein, William Z.
    Deng, Li
    Myer, David L.
    Li, Ya-Qin
    Tischfield, Jay A.
    Stambrook, Peter J.
    Bahassi, El Mustapha
    [J]. NUCLEIC ACIDS RESEARCH, 2010, 38 (09) : 2931 - 2943
  • [2] Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
    Ardizzoni, Andrea
    Boni, Luca
    Tiseo, Marcello
    Fossella, Frank V.
    Schiller, Joan H.
    Paesmans, Marianne
    Radosavljevic, Davorin
    Paccagnella, Adriano
    Zatloukal, Petr
    Mazzanti, Paola
    Bisset, Donald
    Rosell, Rafael
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) : 847 - 857
  • [3] Polo-like kinases and the orchestration of cell division
    Barr, FA
    Silljé, HHW
    Nigg, EA
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (06) : 429 - 440
  • [4] Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer
    Cappuzzo, F
    Hirsch, FR
    Rossi, E
    Bartolini, S
    Ceresoli, GL
    Bemis, L
    Haney, J
    Witta, S
    Danenberg, K
    Domenichini, I
    Ludovini, V
    Magrini, E
    Gregorc, V
    Doglioni, C
    Sidoni, A
    Tonato, M
    Franklin, WA
    Crino, L
    Bunn, PA
    Varella-Garcia, M
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2005, 97 (09): : 643 - 655
  • [5] Cucchi U, 2010, ANTICANCER RES, V30, P4973
  • [6] The small organic compound HMN-176 delays satisfaction of the spindle assembly checkpoint by inhibiting centrosome-dependent microtubule nucleation
    DiMaio, Michael A.
    Mikhailov, Alexei
    Rieder, Conly L.
    Von Hoff, Daniel D.
    Palazzo, Robert E.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2009, 8 (03) : 592 - 601
  • [7] Polo-like kinases and oncogenesis
    Eckerdt, F
    Yuan, JP
    Strebhardt, K
    [J]. ONCOGENE, 2005, 24 (02) : 267 - 276
  • [8] Proteomic screen finds pSer/pThr-binding domain localizing Plk1 to mitotic substrates
    Elia, AEH
    Cantley, LC
    Yaffe, MB
    [J]. SCIENCE, 2003, 299 (5610) : 1228 - 1231
  • [9] A phase I dose escalation trial of BI 2536, a novel Plk1 inhibitor, with standard dose pemetrexed in previously treated advanced or metastatic non-small cell lung cancer (NSCLC)
    Ellis, P. M.
    Chu, Q. S.
    Leighl, N. B.
    Laurie, S. A.
    Trommeshauser, D.
    Hanft, G.
    Munzert, G.
    Gyorffy, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens
    Fossella, FV
    DeVore, R
    Kerr, RN
    Crawford, J
    Natale, RR
    Dunphy, F
    Kalman, L
    Miller, V
    Lee, JS
    Moore, M
    Gandara, D
    Karp, D
    Vokes, E
    Kris, M
    Kim, Y
    Gamza, F
    Hammershaimb, L
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2354 - 2362
1234567